Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711451 | 0.87 | PDE3B (0.49) | CHEK1SMN1; SMN2PDGFRBALDH1A1MAPT | |
| SCHEMBL5247708 | 0.83 | LRRK2 (0.51) | CHEK1MAP2K4NPC1SMN1; SMN2RAB9A | |
| SCHEMBL5246374 | 0.82 | TP53 (0.52) | SMN1; SMN2PDGFRBPDGFRAKDM4EHSD17B10 | |
| SCHEMBL5739630 | 0.81 | MAP2K4 (0.44) | CHEK1MAP2K4SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL5246387 | 0.78 | SMN1; SMN2 (0.40) | PDE10ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5246987 | 0.76 | PDE4A (0.59) | NPC1SMN1; SMN2RAB9APDGFRBALDH1A1 | |
| SCHEMBL18292281 | 0.74 | CHEK1 (0.48) | CHEK1MAP2K4PDE10ANPC1SMN1; SMN2 | |
| SCHEMBL4713601 | 0.72 | BCHE (0.47) | SMN1; SMN2ALDH1A1KDM4EMAPK1HSD17B10 | |
| SCHEMBL5249079 | 0.72 | PDE4A (0.45) | SMN1; SMN2PDGFRBALDH1A1MAPTKDM4E | |
| SCHEMBL4711596 | 0.71 | DCUN1D1 (0.45) | SMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | claimed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1644371-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | AVENTIS PHARMA INC (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | NFKBIA, IKBKB, IKBKG | CHEK1 536/4885MAP2K4 348/4885PDE10A 2607/4885 |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | CHEK1 133/4885MAP2K4 191/4885PDE10A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.